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Cannabinoid signaling by CB1 receptors drives fibrogenesis and fat accumulation in liver. A report in this
issue of Cell Metabolism (Jeong et al., 2008) now links hepatic stellate cells, a resident liver fibrogenic cell
type, to the generation of steatosis through production of the endocannabinoid 2-arachidonoylglycerol
(2-AG) after ethanol feeding, leading to paracrine stimulation of hepatocyte CB1 receptors.For years, a fatty liver was typically con-
sidered an innocuous and transient con-
sequence of alcohol ingestion, obesity,
or occasionally prescription drugs. More
recently, however, the metabolic and
pathogenic costs of fat accumulation in
liver have become increasingly apparent.
Fat generates inflammatory signals and
reactive oxygen species that can amplify
liver injury and stimulate fibrosis, or scar-
ring. In particular, induction of cytochrome
P450 2E1 (CYP2E1) by ethanol is a critical
response following chronic ethanol inges-
tion and in nonalcoholic fatty liver disease
(NAFLD) that leads to enhanced genera-
tion of reactive oxygen species and liver
injury (Dey and Cederbaum, 2006; Nieto
et al., 2002). Even in ‘‘bland’’ steatosis
due to alcohol, where inflammatory cells
are lacking, early activation of resident
fibrogenic cells (hepatic stellate cells) is
already apparent (Reeves et al., 1996).
Thus, the main diseases characterized
by hepatic steatosis—alcoholic fatty liver
and NAFLD—are recognized as harbin-
gers of worse disease to follow when liver
insult is sustained. Additionally, the pres-
ence of fat in patients with hepatitis C
(HCV) infection independently accelerates
progressionof fibrosis to cirrhosis, theend
stage of sustained liver injury (Leandro
et al., 2006). All of thesehepatic conditions
are highly pervasive and increasing world-
wide. In this context, the findings of Jeong
et al. (2008) reported in this issue of Cell
Metabolism offer a clinically important
new mechanism to explain fat accumula-
tion in liver through a conspiracy of cell-
cell interactions between neighboring
cell types.
With the recognition that fat accumula-
tion contributes to disease, attention has
turned toward understanding its patho-genesis. In particular, metabolic pathways
regulating fat in liver have been closely
scrutinized, with evidence of both en-
hanced lipogenesisanddecreased lipolysis
in diseases associated with steatosis.
Adipokines, oxidant stress, andmitochon-
drial injury have been implicated as well
(Albano,2006).While these localmetabolic
factors have provided ample explanation
for fat accumulation, they have focused
primarily on the role of hepatocytes, the
metabolic workhorse of liver, and not on
potential contributions of other, nonparen-
chymal cell types, including hepatic mac-
rophages (Kupffer cells), stellate cells,
and sinusoidal endothelial cells. The study
by Jeonget al. (2008) nowconvincingly im-
plicates hepatic stellate cells as important
paracrine mediators of steatosis in liver.
Added to the burden of disease due to
alcohol are additional morbidities con-
ferred by other drugs of abuse, in particu-
lar cannabis,which is a risk factor for fibro-
sis progression in chronic liver disease
due to HCV and possibly other etiologies
(Hezode et al., 2005). These and related
epidemiologic studies have coupled can-
nabinoids to the pathogenesis of liver dis-
ease, as underscored by a series of stud-
ies demonstrating that whereas the CB1
cannabinoid receptor is profibrogenic
toward the activated hepatic stellate cell,
the CB2 receptor has the opposite effect
(Mallat et al., 2007). Thus, the CB1 recep-
tor antagonist rimonabant not only blunts
the central effects of CB1 on appetite sup-
pression but also has an independent
effect in blocking hepatic fibrogenesis
(Mallat et al., 2007).
At the same time, cannabinoids also
promote the development of fatty liver,
since CB1 stimulation in mice induces
hepatic fatty acid synthesis whereas CB1Cell Metaboreceptor knockout mice are resistant
to diet-induced obesity (Osei-Hyiaman
et al., 2005). Moreover, daily marijuana
use is a risk factor for steatosis in HCV-
infected individuals (Hezode et al., 2008).
The mechanisms underlying cannabi-
noid-mediated steatosis have remained
obscure, however.
Jeong et al. (2008) have introduced a vi-
tal link in this chain connecting cannabi-
noids to the steatotic effects of ethanol,
unearthing a surprising new role for he-
patic stellate cells. These resident non-
parenchymal cells are adjacent to hepato-
cytes and surround the hepatic vascular
unit, or sinusoid, harboring a broad range
of functions in normal and injured liver
(Friedman, 2008). In liver injury, stellate
cells undergo a characteristic ‘‘activa-
tion’’ into fibrogenic cells that secrete
a range of cytokines, reactive oxygen
species, and inflammatory mediators.
Remarkably, the Jeong et al. study
demonstrates that the endocannabinoid
2-arachidonoylglycerol (2-AG) is among
those factors secreted by activated stel-
late cells during liver injury due to ethanol
feeding. Furthermore, induction of endo-
cannabinoids was restricted to 2-AG,
since anandamide, another endogenous
cannabinoid, was not elevated by etha-
nol. Although mouse models of ethanol
administration do not recapitulate the full
spectrum of inflammation and injury
seen in human disease, they do elicit stea-
tosis and oxidant stress, and thus the
finding that ethanol feeding stimulates
2-AG levels is likely to be relevant to hu-
man alcoholic liver disease. On the other
hand, 2-AG stimulation is not simply a di-
rect effect of alcohol or its metabolites on
stellate cells, since ethanol did not induce
2-AG production in cultured stellate cells.lism 7, March 2008 ª2008 Elsevier Inc. 187
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PreviewsRather, a more likely pathway—and one
that should be tested in future studies—
is one wherein ethanol metabolism by he-
patocytes generates paracrine signals
that drive 2-AG synthesis by stellate cells.
Paracrine stimulation of CB1 receptor
signaling in hepatocytes by 2-AG derived
from neighboring stellate cells is a major
finding of the Jeong et al. study. The
importance of hepatocyte responses to
2-AG was confirmed first by using rimo-
nabant to attenuate CB1 signaling and
thereby block steatosis in vivo, and then
by assessing the effects of ethanol in
mice selectively deficient in CB1 recep-
tors only in hepatocytes. These liver-
specific CB1 receptor knockout mice are
particularly useful in that they avoid any
confounding effects of CB1 signaling in
the central nervous system, where the re-
ceptor is far more abundantly expressed
than in liver. Animals with hepatocyte-
specific deletion of CB1 receptors were
resistant to the steatotic effects of ethanol
feeding. Moreover, induction of the lipo-
genic mediators sterol regulatory ele-
ment-binding protein 1c (SREBP-1c) and
fatty acid synthase (FAS) was blunted
and activity of carnitine palmitoyltransfer-
ase 1 (CPT1) was no longer inhibited in
mice with either global or hepatocyte-
specific deletion of CB1 receptors. It
would be informative to determine
whether CYP2E1 expression is addition-PPARg: Ally and F
Walter Wahli1,*
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The Italian anatomist Niccolo` Massa un-
doubtedly appreciated the paramount im-
portance of bones when he wrote as early
as 1559 that ‘‘if any one is ignorant of the
188 Cell Metabolism 7, March 2008 ª2008 Eally affected by CB1 loss, as this could at-
tenuate liver injury by reducing oxidative
stress.
The intriguing findings of Jeong et al.
(2008) introduce a new paradigm in our
understanding of fatty liver and its poten-
tial attenuation by available pharmacolog-
ical agents. Paracrine signaling by a non-
parenchymal cell to modulate hepatocyte
responses may be relevant to a number of
intermediary pathways apart from fat me-
tabolism, including homeostasis of carbo-
hydrates, proteins, vitamins, and metals
(especially iron and copper). Effects of
Kupffer cells and sinusoidal endothelial
cells as other sources of paracrine stimuli
should also be considered in order to dis-
sect whether these effects derive exclu-
sively from stellate cells, although this
seems unlikely. It is possible, but still
unproven, that the paracrine pathway de-
scribed by Jeong et al. (2008) could con-
tribute to fatty liver due to etiologies other
than alcohol, especially NAFLD.
In summary, the uncovering of para-
crine cannabinoid signaling as a determi-
nant of hepatic steatosis unveils exciting
new possibilities for both understanding
and regulating fat accumulation in liver.
Combined with data implicating cannabi-
noids in hepatic fibrogenesis, this path-
way is assuming a central role in the reg-
ulation of hepatic metabolism, injury,
and fibrosis.oe in Bone Metabo
search Center Frontiers in Genetics, University
ed process that is largely dependen
rbing osteoclasts. A new study (Wan
tion factor PPARg in promoting bo
structure of the bones it follows necessar-
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